natgillin/translations-raw huggingface dataset:
The combination for use according to claim 5, wherein the composition comprising nanoparticles and the platinum-based agent are administered sequentially, simultaneously, or concurrently. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 5, naznačena time što se pripravak koji sadrži nanočestice i sredstvo na bazi platine primijenjuje uzastopno, istodobno ili paralelno.
The combination for use according to claim 5, wherein the platinum-based agent is carboplatin. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 5, naznačena time što je sredstvo na bazi platine karboplatin.
The composition or combination for use according to anyone of the preceding claims, wherein the individual has received a prior platinum-based chemotherapy and has a treatment free interval of more than about 12 months since the completion of the platinum-based chemotherapy. 
Pripravak ili kombinacija namijenjeni upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što je osoba prethodno primila kemoterapiju na bazi platine i ima interval bez liječenja dulji od otprilike 12 mjeseci nakon dovršenja kemoterapije na bazi platine.
The composition or combination for use according to claim 9, wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is Nab-paclitaxel. 
Pripravak ili kombinacija namijenjeni upotrebi u skladu s patentnim zahtjevom 9, naznačeni time što pripravak sadrži nanočestice koje sadrže taksan, a protein-nosač je Nab-paklitaksel.
The composition for use according to claim 1 or the combination for use according to claim 5, wherein the individual has received a prior chemotherapy and has a treatment free interval for more than about 6 months prior to the initiation of the treatment. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 5, naznačeni time što je osoba prethodno primila kemoterapiju i ima interval bez liječenja dulji od otprilike 6 mjeseci prije početka liječenja.
The composition or combination for use according to anyone of the preceding claims, wherein the individual does not show a symptom of hypersensitivity prior to the initiation of the treatment. 
Pripravak ili kombinacija namijenjeni upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što osoba ne pokazuje simptom preosjetljivosti prije početka liječenja.
The composition or combination for use according to anyone of the preceding claims, wherein the individual does not show a symptom resulting from the recurrent cancer upon completion of the treatment. 
Pripravak ili kombinacija namijenjeni upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što osoba ne pokazuje simptom koji je posljedica recidiva raka nakon dovršenja liječenja.
Pimobendan for use in a method according to any one of claims 1 to 2, wherein pimobendan is utilized in oral or parenteral form. 
Pimobendan za uporabu u postupku prema zahtjevu 1, naznačen time, da se pimobendan primjenjuje u oralnom ili parenteralnom obliku.
A composition according to claim 1, wherein the components a), b) and c) comprise substantially the entire composition. 
Postupak prema zahtjevu 1, naznačen time da komponente a), b) i c) u većoj mjeri čine cijelu rashladnu tvar.
A low temperature refrigeration system comprising a condenser, an evaporator and a refrigerant composition according to any one of claims 1-3, wherein the evaporator temperature of the refrigeration system is below 0°C. 
Rashladni sustav koji se sastoji od kondenzatora, isparivača i rashladne tvari kako je definirano u bilo kojem zahtjevu od 1 do 3, naznačen time da je temperatura isparivača u rashladnom sustavu ispod 0°C.
A system according to any one of claims 10-13, wherein the refrigeration system is suitable for use with chlorodifluoromethane (HFC-22) and the composition according to any one of claims 1-3 is substituted for HFC-22 in the system. 
Sustav prema bilo kojem zahtjevu od 12 to 18, naznačen time da je rashladni sustav pogodan za korištenje sa klorodifluorometanom (HFC-22) i rashladna tvar kako je definirana u bilo kojem zahtjevu od 1 do 3 je zamjena za HFC-22 u sustavu.
A process for producing biodegradable polymeric materials including polyhydroxyalkanoates (PHAs) from an organic carbon source, which comprises: 
Postupak proizvodnje biorazgradivih polimernih materijala, uključujući polihidroksialkanoate (PHA) iz organskog izvora ugljika, naznačen time što se sastoji u:
cultivating PHA-producing microbial cells in a medium solution containing an organic carbon source to form PHAs that are accumulated in the cells as inclusion bodies; 
uzgoju mikrobnih stanica koje proizvode PHA u tekućem mediju koji sadrži organski izvor ugljika kako bi se dobilo PHA koji se nakupljaju u stanicama u obliku inkluzijskih tijela;
separating the PHA solid from the cell debris solution; 
odvajanju čvrstog PHA od otopine staničnog debrija;
feeding the cell debris solution to the cultivation step (a). 
dodavanju otopine staničnog debrija u korak uzgoja (a).
The process according to claim 1, wherein the solubilizing step (b) is carried out by: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se korak solubiliziranja (b) provodi:
(b2) adjusting the pH of the first suspension to a value of from 7 to 11 to obtain a second suspension of the PHA solid in a basic cell debris solution. 
(b2) podešavanje pH prve suspenzije do vrijednosti od 7 do 11 kako bi se dobilo drugu suspenziju čvrstog PHA u bazičnoj otopini staničnog debrija.
The process according to claim 2, wherein a separating step (c1) is carried out on the first suspension and the resulting acidic cell debris solution is fed according to step (d). 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se korak odvajanja (c1) provodi kod prve suspenzije, a dobivenu kiselu otopinu staničnog debrija se dodaje prema koraku (d).
The process according to claim 3, wherein a separating step (c2) is carried out on the second suspension and the resulting basic cell debris solution is fed according to step (d). 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što korak odvajanja (c2) se provodi kod druge suspenzije, a dobivenu bazičnu otopinu staničnog debrija se dodaje prema koraku (d).
The process according to claim 2, wherein a separating step (c3) is carried out on the second suspension and the resulting acid-base cell debris solution is fed according to step (d). 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se korak odvajanja (c3) provodi kod druge suspenzije, a dobivenu kiselo-bazičnu otopinu staničnog debrija se dodaje prema koraku (d).
The process according to anyone of the previous claims, wherein the total amount of cell debris fed to the cultivation step (a) is from 5 to 50% by weight with respect to the amount of the glucose-equivalent carbon substrate. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ukupna količina staničnog debrija koju se dodaje u korak uzgoja (a) je od 5 do 50%, težinski, u odnosu na količinu glukoznog ekvivalenta ugljičnog supstrata.
The process according to claim 3, wherein the amount of the acidic cell debris solution (ACDS) fed to step (b) is from 5 to 20% by weight with respect to the weight of the glucose-equivalent carbon substrate. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je količina kisele otopine staničnog debrija (ACDS) koju se dodaje u korak (b) od 5 do 20%, težinski, u odnosu na težinu glukoznog ekvivalenta ugljičnog supstrata.
The process according to claim 2, wherein the adjusting step (b2) comprises adding at least one surfactant to the first suspension. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se korak podešavanja (b2) sastoji u dodavanju najmanje jednog surfaktanta u prvu suspenziju.
The process according to anyone of claims from 2 to 10, wherein the solubilizing step (b1) comprises adding an aqueous solution of a strong acid to the non-PHA cell mass. 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 2 do 10, naznačen time što se korak solubiliziranja (b1) sastoji u dodavanju vodene otopine jake kiseline u staničnu masu koja nije PHA.
The process according to anyone of claims 2 to 13, wherein the adjusting step (b2) comprises adding an aqueous solution of at least one strong base to the first suspension. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 2 do 13, naznačen time što se korak podešavanja (b2) sastoji u dodavanju vodene otopine najmanje jedne jake baze u prvu suspenziju.
A process according to claim 1, wherein the components a), b) and c) comprise substantially the entire refrigerant composition. 
Postupak prema zahtjevu 1, naznačen time da komponente a), b) i c) u većoj mjeri čine cijelu rashladnu tvar.
A process according to claim 1 or 2, wherein the refrigerant composition comprises a) about 30 wt% difluoromethane (HFC-32), b) about 30 wt% pentafluoroethane (HFC-125), and c) about 40 wt% tetrafluoroethane (HFC-134a). 
Postupak prema zahtjevu 1 ili 2, naznačen time da rashladna tvar sadrži a) oko 30 tež.% difluorometana (HFC-32), b) oko 30 tež.% pentafluoroetana (HFC-125), i c) oko 40 tež.% tetrafluoroetana (HFC-134a).
A process according to any of claims 1 to 3, wherein the evaporator temperature of the system is in the range of below 0°C (32°F) to -30°C (-22°F). 
Postupak prema bilo kojem zahtjevu od 1 do 3, naznačen time da je temperatura isparivača u sustavu u rasponu od ispod 0°C (32°F) do -30°C (-22°F).
A process according to any preceding claim, wherein the refrigerant composition has an operating characteristic of superheat during refrigeration of at least 1.1°C (2°F). 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da rashladna tvar ima radnu karakteristiku pregrijavanja tijekom hlađenja od barem 1.1°C (2°F).
A process according to any preceding claim, wherein the refrigerant composition has an operating characteristic of superheat during refrigeration in the range of: 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da rashladna tvar ima radnu karakteristiku pregrijavanja tijekom hlađenja u rasponu od:
A process according to any preceding claim, wherein the refrigeration system is suitable for use with chlorodifluoromethane (HFC-22) and the refrigerant composition is subsituted for HFC-22 in the system. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da je rashladna tvar pogodna za upotrebu sa klorodifluorometanom (HFC-22) i rashladna tvar zamjenjuje tvar HFC-22 u sustavu.
A refrigeration system comprising a condenser, an evaporator and a refrigerant composition as defined in any of claims 1 to 3, wherein the evaporator temperature of the refrigeration system is below 0°C. 
Rashladni sustav koji se sastoji od kondenzatora, isparivača i rashladne tvari kako je definirano u bilo kojem zahtjevu od 1 do 3, naznačen time da je temperatura isparivača u rashladnom sustavu ispod 0°C.
A system according to claim 12, wherein the evaporator temperature of the refrigeration system is -30°C (-22°F) or below. 
Sustav prema zahtjevu 12, naznačen time da je temperatura isparivača u rashladnom sustavu -30°C (-22°F) ili niža.
A system according to claim 12, wherein the evaporator temperature of the system is in the range of below 0°C (32°F) to -30°C (-22°F). 
Sustav prema zahtjevu 12, naznačen da je temperatura isparivača u rashladnom sustavu u rasponu od ispod 0°C (32°F) do -30°C (-22°F).
A system according to any one of claims 12 to 16, wherein the refrigerant composition has an operating characteristic of superheat during refrigeration of at least 1.1°C (2°F). 
Sustav prema bilo kojem zahtjevu od 12 do 16, naznačen time da rashladna tvar ima radnu karakteristiku pregrijavanja tijekom hlađenja od barem 1.1°C (2°F).
A system according to any one of claims 12 to 17, wherein the refrigerant composition has an operating characteristic of superheat during refrigeration in the range of: 
Sustav prema bilo kojem zahtjevu od 12 do 17, naznačen time da rashladna tvar ima radnu karakteristiku pregrijavanja tijekom hlađenja u rasponu od:
A system according to any one of claims 12 to 18, wherein the refrigeration system is suitable for use with chlorodifluoromethane (HFC-22) and a refrigerant composition as defined in any one of claims 1 to 3 is substituted for HFC-22 in the system. 
Sustav prema bilo kojem zahtjevu od 12 to 18, naznačen time da je rashladni sustav pogodan za korištenje sa klorodifluorometanom (HFC-22) i rashladna tvar kako je definirana u bilo kojem zahtjevu od 1 do 3 je zamjena za HFC-22 u sustavu.
A system according to claim 12, wherein the refrigerant composition is as defined in claim 3, and wherein the system is a freezer operable at a box temperature of -26.1 °C (-15°F). 
Sustav prema zahtjevu 12, naznačen time da je rashladna tvar kako je definirana u zahtjevu 3, te pri čemu je sustav hladnjak koji radi na temperaturi od -26.1 °C (-15°F).
A method of producing a coffee extract, comprising: 
Postupak dobivanja ekstrakta kave, koji se sastoji u:
The method of any of the preceding claims further comprising grinding the coffee beans before or after step a). 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se dodatno sastoji u mljevenju zrna kave prije ili nakon koraka a).
A capsule for preparing a beverage by injection of a fluid, comprising a closed chamber and a means for allowing the said beverage to flow out, the closed chamber of said capsule comprising ground green coffee beans that has been heat treated at a temperature between 100°C and 180°C for at least 5 minutes, keeping the moisture level between 6% and 20% of the total weight of the coffee beans, wherein the green coffee beans have not been subjected to roasting. 
Kapsula za pripravu napitaka injiciranjem tekućine, koja sadrži zatvorenu komoru i napravu koja omogućuje istjecanje navedenog napitka, gdje zatvorena komora navedene kapsule sadrži mljevena sirova zrna kave, toplinski obrađena na temperaturi između 100 °C i 180 °C u trajanju od najmanje 5 minuta, uz održavanje razine vlage između 6% i 20% od ukupne težine zrna kave, naznačena time što sirova zrna kave nisu podvrgnuta prženju.
reacting said intermediate derivative with iodine; and 
reakcija tog među-derivata s jodom; i
The process according to claim 1, wherein said electrochemical oxidation is carried out in an electrolytic cell wherein the anodic and cathodic compartments are separated by a ion permeable membrane. 
Postupak prema zahtjevu 1, gdje se elektrokemijska oksidacija provodi u elektrolitičkoj ćeliji gdje su anodni i katodni odjeljci odvojeni membranom propusnom za ione.
The process according to any one of claims 1-5, in the presence of a cathode solvent system comprising: a strong acid mixed with water, a C1-C4 alcohol or mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1-5, u prisutnosti sustava katodnog otapala koji sadrži: jaku kiselinu pomiješanu s vodom, C1-C4 alkohol ili njihovu mješavinu.
The process according to claim 6, wherein said strong acid is hydrochloric acid or sulphuric acid. 
Postupak prema zahtjevu 6, gdje je ta jaka kiselina klorovodična kiselina ili sumporna kiselina.
The process according to any one of claims 6-7, wherein said cathode solvent system comprises a mixture of water and hydrochloric acid. 
Postupak prema bilo kojem od zahtjeva 6-7, gdje sustav katodnog otapala sadrži mješavinu vode i klorovodične kiseline.
The process according to claim 8 wherein said hydrochloric acid has a concentration comprised from 5% to 40% by weight. 
Postupak prema zahtjevu 8 gdje klorovodična kiselina ima koncentraciju u rasponu od 5% do 40% težinski.
The process according to claim 1, comprising transferring the solution obtained in step-a into a separate reactor, before carrying out the next step-b. 
Postupak prema zahtjevu 1, obuhvaća prijenos otopine dobivene u koraku (a) u zasebni reaktor, prije provođenja sljedećeg koraka (b).
The process according to claim 14 further comprising the preparation of Iomeprol or Iopamidol from compound II as above defined. 
Postupak prema zahtjevu 14 koji dalje obuhvaća pripremu Iomeprola ili Iopamidola iz spoja II kako je definiran gore.
An isolated monoclonal antibody or antigen binding portion thereof of any one of claims 1 to 7 or a composition of claim 8 for use in a method of treating cancer, wherein the cancer is optionally selected from melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, clear cell sarcoma, and prostate cancer. 
Protutijelo ili njegov dio za vezanje na antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 8, za uporabu u skladu s patentnim zahtjevom 18, naznačen time, da je karcinom gušterače, melanom, karcinom dojke, karcinom jajnika, karcinom bubrega, gastrointestinalni/karcinom debelog crijeva, karcinom pluća, sarkom ili karcinom prostate.
Atomiser according to claim 1, characterised in that the counter device (23) is designed so that the atomiser (1) is locked against further operation and/ or insertion of a new container (3) in the second locked state. 
Raspršivač prema zahtjevu 1, naznačen time, da je uređaj za brojanje (23) konstruiran tako da je raspršivač (1) zatvoren za daljnju radnu operaciju i/ili umetanje novog spremnika (3) u drugom zatvorenom stanju.
Atomiser according to claims 7 and 9, characterised in that the locking device (78) is arranged on the part or that in the first and/or second locked state rotation of the part relative to the atomiser (1) and/or operation of the locking element (8) are blocked. 
Raspršivač prema zahtjevima 7 i 9, naznačen time, da je zaporni uređaj (78) raspoređen na pokretnom ili okretnom dijelu ili da su blokirani, u zatvorenom stanju, i okretanje dijela u odnosu na raspršivač (1) i/ili radna operacija zapornog elementa (8).
Atomiser according to claim 9 and 11, characterised in that the locking device (78) has a control part (45), which in particular can be moved peripherally in relation to the longitudinal, rotational or movement axis of the atomiser (1), for operation or movement of the lock part (41). 
Raspršivač prema zahtjevima 9 i 11, naznačen time, da zaporni uređaj (78) ima upravljač (45) koji se posebno može pokretati periferno u odnosu na uzdužnu, rotacijsku ili pokretnu os raspršivača (1), za rad ili pokretanje ključa (41).
Atomiser according to claims 8 and 12, characterised in that the control part (45) can be operated or moved by the rider (49), in particular parallel to the axis, in order to achieve a blocking of the atomiser (1) or a locked state. 
Raspršivač prema zahtjevima 8 i 12, naznačen time, da upravljač (45) može raditi ili se pokretati pomoću pokretnog utega (49), posebno paralelno na os, kako bi postigao zaustavljanje raspršivača (1) ili kako bi postigao zatvoreno stanje.
Atomiser according to claim 12 or 13, characterised in that the control part (45), during operation, in particular tensioning, of the atomiser (1) for operation of the lock part (41) can be moved, in particular displaced peripherally, with particular preference only after a previous displacement parallel to the axis. 
Raspršivač prema zahtjevu 12 ili 13, naznačen time, da se upravljač (45) može pokretati, za vrijeme radne operacije raspršivača (1), posebno kod naprezanja, za rad ključa (41), posebno se on može periferno premještati, s osobitim naglaskom samo nakon prethodnog premještanja paralelno na os.
Atomiser according to one of the preceding claims, characterised in that the first and/or second locked state cannot be reversed, and/or that the pressurisation or atomisation takes place in a purely mechanical fashion, in particular without propellant gas, preferably by spring power, and/or that the atomiser (1) is designed as a portable inhaler, in particular for medicinal aerosol therapy. 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da se zatvoreno stanje ne može vratiti na početak, i/ili da se tlačenje ili raspršivanje provodi na čisto mehanički način, posebno bez pogonskog plina, poželjno pomoću snage opruge, i/ili da je raspršivač (1) konstruiran kao prijenosni inhalator, posebno za medicinsku aerosolnu terapiju.
Atomiser according to claims 2, 22 and 25, characterised in that the locking device (78) is arranged on the part or that in the first and/or second locked state rotation of the part relative to the atomiser (1) and/or operation of the locking element (8) are blockable. 
Raspršivač prema zahtjevima 7 i 9, naznačen time, da je zaporni uređaj (78) raspoređen na pokretnom ili okretnom dijelu ili da su blokirani, u zatvorenom stanju, i okretanje dijela u odnosu na raspršivač (1) i/ili radna operacija zapornog elementa (8).
Atomiser according to one of the preceding claims, characterised in that the first and/or second locked state is not reversable, and/or that the pressurisation or atomisation is mechanically driven, in particular without propellant gas, preferably by spring power, and/or that the atomiser (1) is a portable inhaler, in particular for medicinal aerosol therapy. 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da se zatvoreno stanje ne može vratiti na početak, i/ili da se tlačenje ili raspršivanje provodi na čisto mehanički način, posebno bez pogonskog plina, poželjno pomoću snage opruge, i/ili da je raspršivač (1) konstruiran kao prijenosni inhalator, posebno za medicinsku aerosolnu terapiju.
n is 0 or 1; and R stands for arginine, wherein said peptide exhibits a peptone biological activity, for promoting cell growth and/or cell density and/or cell viability, and/or production efficiency of heterologous polypeptides in recombinant host cultures. 
n je 0 ili 1; i R predstvlja arginin, pri čemu spomenuti peptid izražava biološku aktivnost peptona, za pospješivanje rasta stanice i/ili gustoće stanice i/ili održivosti stanice i/ili proizvodne djelotvornosti heterolognih polipeptida u rekombinantnim kulturama domaćina.
A combinatorial peptide library consisting of peptides of the formula (X1)nX2R wherein X1 and X2 may be identical or different and independently represent any amino acid other than arginine; 
Kombinacijska biblioteka peptida, naznačena time, da sadrži peptide formule (X1)nX2R gdje X1 i X2 mogu biti isti ili različiti i neovisno predstavljaju bilo koju amino kiselinu koja nije arginin;
n is 0 or 1; and R stands for arginine, wherein at least some of said peptides exhibit a peptone biological activity, for promoting cell growth and/or cell density and/or cell viability, and/or production efficiency of heterologous polypeptides in recombinant host cultures. 
n je 0 ili 1; i R predstavlja arginin, pri čemu barem neki od spomenutih peptida izražavaju biološku aktivnost peptona, za pospješivanje rasta stanice i/ili gustoće stanice i/ili održivosti stanice i/ili proizvodne djelotvornosti heterolognih polipeptida u rekombinantnim kulturama domaćina.
A compound as defined in any one of claims 1 to 5, in free or salt form, for use as a pharmaceutical. 
Spoj kako je definiran u bilo kojem od zahtjeva 1 do 5, u slobodnom obliku ili obliku soli, za uporabu kao farmaceutik.
The compound or composition for use in the method of claim 8, wherein the condition is: 
Spoj ili pripravak za uporabu u postupku prema zahtjevu 8, gdje je stanje:
cognitive impairment; narcolepsy; or 
kognitivni poremećaj; narkolepsija; ili seksualna disfunkcija u žena.
The compound or composition for use in the method of claim 9, wherein the condition is narcolepsy and the method further comprises administering a compound or compounds selected from central nervous system stimulants, modafinil, antidepressants, and gamma hydroxybutyrate, to a patient in need thereof. 
Spoj ili pripravak za uporabu u postupku prema zahtjevu 9, gdje je stanje narkolepsija i postupak dalje obuhvaća primjenu spoja ili spojeva izabranih između stimulansa središnjeg živčanog sustava, modafinila, antidepresiva i gama hidroksibutirata, bolesniku kojemu je to potrebno.